Alexion Pharmaceuticals, Inc. kicked off the trading day on 09/10/19 with a price increase of 3.01%, equivalent to $3.2 relative change for the day. Taking a more long-term approach, ALXN had a 52-week range of $92.56 to $141.86. At the time of this article’s publishing, this stock is trading at $109.60 after starting the trading session at $106.02. At the time of writing, this stock’s 50-day Moving Average stands at $115.17, while the 200-day Moving Average of this stock is currently $121.80.
Currently, this company’s share volume is sitting at $3,768,382, but has maintained average daily volume of $2.27M. This stock has generated an average Year to Date volume of $1.8 million, alongside an average 20-day volume of $3.26 million. This publicly-traded company’s shares outstanding now amounts to $224.20 million, simultaneously with a float of $223.75 million. The organization now has a market capitalization sitting at $24.57 billion.
Alexion Pharmaceuticals, Inc.(ALXN) Ownership Data
Now let’s turn our focus to how large-scale investors are behaving with this stock. Alexion Pharmaceuticals, Inc.’s current insider ownership accounts for 0.20%, in contrast to 97.70% institutional ownership. According to the most recent latest insider trade that took place on Jul 01 this organization’s EVP, Chief Compliance Officer sold 4,500 at the rate of 132.78, making the entire transaction hit 597,510 in total value, affecting insider ownership by 29,627. Preceding that transaction, on Jun 21 Company’s Chief Strategy & Business Off sold 578 at a price of 132.00, making the whole transaction’s value amount to 76,296. This particular insider is now the holder of 30,201 in total.
If we take a glance at the Ownership summary of Alexion Pharmaceuticals, Inc.’s stock, Institutional holders make up 97.70% of its total stock ownership. All together, they are the legal holders of 224.20M shares. If we focus on the top 3 stockholders for this publicly-traded organization, Fidelity Management & Research Co. owns 24,306,733 shares, with The Vanguard Group, Inc. in 2nd place owning 16,328,757 shares and T. Rowe Price Associates, Inc. (Investment Management) in third place with total ownership of 14,085,352 shares.
Alexion Pharmaceuticals, Inc. (ALXN) Earnings and Revenue Data
In the latest quarterly report that this company released, which was put into the public domain on 6/29/2019, the organization reported $2.64 earnings per share (EPS) for the three-month period, surpassing the consensus estimate (set at $2.34) by $0.3.
This company achieved a net margin of 29.64 while generating a return on equity of 14.2. Alexion Pharmaceuticals, Inc.’s full-quarter revenue increased by 23.3%, when compared against the year-ago quarter. Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.43 per share during the current fiscal year.
Alexion Pharmaceuticals, Inc.’s EPS decrease for this current 12-month fiscal period is -95.70%, and is forecasted to reach 10.67% in the upcoming year. Looking at the long run, market analysts have predicted that Company’s EPS will increase by 16.84% through the next 5 years, which can be compared against the -40.60% growth it accomplished over the previous five years trading on the market.
Additional Trading Performance Indicators
Now turning our attention to the current performance indicators for Alexion Pharmaceuticals, Inc., this organization’s Quick Ratio in the last reported quarter now stands at 3.60. The company has managed to achieve an average true range (ATR) of 4.78. Alongside those, its PE Ratio stands at $19.96, and its Beta score is 1.68.
Another valuable indicator worth considering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.46 for this organization. Similarly, its price to free cash flow for trailing twelve months is now 19.31. Plus, this company’s price to book ratio for the last three-month fiscal period reported is 2.42, whereas its price to cash per share for the last quarter landed at 9.32.
In the same vein, ALXN’s Diluted EPS (Earnings per Share) trailing twelve months was posted at 5.49, a figure that is expected to reach 2.47 in the next reported quarter, and analysts expect it will be 10.67% at the market close of one year from today’s date.